Are you a medical professional seeking the latest information on treating Irritable Bowel Syndrome (IBS)? Look no further than plecanatide, also known as Trulance - a promising new medication that has been shown to effectively relieve IBS symptoms. In this review of recent studies, we'll take a closer look at plecanatide and how it works, as well as any potential side effects you should be aware of. Keep reading to learn more about this exciting treatment option for your patients with IBS.
Plecanatide is a medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It belongs to a class of drugs called guanylate cyclase-C agonists, which stimulate the secretion of fluid in the intestines.
Unlike other medications that treat these conditions, plecanatide specifically targets the GC-C receptors found on intestinal cells. This selective targeting allows for more effective treatment with fewer side effects.
Plecanatide comes in tablet form and is taken orally once daily. The recommended dose for CIC is 3 mg per day, while the recommended dose for IBS-C is 1 mg per day.
Plecanatide offers an alternative option for those suffering from CIC and IBS-C. Its targeted approach can lead to effective relief without as many negative side effects commonly associated with traditional treatments.
Plecanatide is an FDA-approved medication used to treat chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It works by binding to the guanylate cyclase-C receptor located on the surface of intestinal cells.
When plecanatide binds to this receptor, it stimulates the production of cyclic guanosine monophosphate (cGMP), which promotes fluid secretion into the intestines. This increased fluid helps soften stool, making it easier to pass through the digestive tract.
Furthermore, plecanatide also reduces visceral hypersensitivity in people with IBS-C. Visceral hypersensitivity refers to a heightened sensitivity of internal organs such as the gut, leading to pain and discomfort associated with IBS symptoms like bloating and cramping.
By reducing visceral hypersensitivity, plecanatide can alleviate these uncomfortable symptoms for patients suffering from IBS-C. Plecanatide's mechanism of action provides relief for those who struggle with chronic constipation or IBS-C.
While plecanatide has shown to be effective in treating irritable bowel syndrome, it's important to consider the potential side effects. Like any medication, there can be some negative reactions that patients may experience.
Common side effects of plecanatide include diarrhea, abdominal pain, nausea and vomiting. These symptoms are typically mild to moderate in severity and will often improve over time as the patient continues with treatment.
Plecanatide is a promising treatment option for patients suffering from irritable bowel syndrome with constipation. It works by targeting the guanylate cyclase-C receptor and increasing fluid secretion in the intestines to promote regular bowel movements.
Recent studies have shown that plecanatide is effective in improving symptoms of IBS-C and has a favorable safety profile. However, as with any medication, there are potential side effects that should be carefully monitored.
Medical professionals can confidently consider prescribing plecanatide to their patients with IBS-C who have not responded well to other treatments or who experience bothersome side effects from current therapies.
The availability of plecanatide provides an important new tool for managing this common digestive disorder and improving quality of life for affected individuals.
1.
New surgical method shows promising results for cervical cancer treatment
2.
Babies Are Bleeding to Death as Parents Reject a Vitamin Shot Given at Birth
3.
GuCS Future Focus: Future Focus from the Genitourinary Cancers Symposium
4.
Study confirms safety and efficacy of higher-dose-per-day radiation for early-stage prostate cancer
5.
Can Prior Authorization Be Better With Artificial Intelligence?
1.
Checkpoint Inhibitors in Oncology: Advances in PD-1/PD-L1 and CTLA-4 Targeted Therapy
2.
Public Health Strategies for Improving Cancer Survivorship Support Systems
3.
Analyzing the Mechanisms and Efficacy of Carboplatin, Abraxane, and Albumin-Bound Formulations
4.
Treating Methemoglobinemia: What You Need to Know Now!
5.
Red Cell Deformability as a Target in Critical Illness
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
2.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
3.
Understanding the Multifaceted Advantages of CDK4/6 Inhibitors in HR+/HER2- PALOMA 2 Study.
4.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
5.
Updates on Standard V/S High Risk Myeloma Treatment
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation